News & Events

Teikoku Pharma USA and Eagle Pharmaceuticals Enter into License Agreement for Docetaxel, Non-Alcohol Formula

October 15, 2015

Teikoku Pharma USA Inc. (“TPU”) today announced that it has entered into an exclusive license agreement with Eagle Pharmaceuticals, Inc. to market, sell, and distribute TPU’s Docetaxel Injection, Non-Alcohol Formula in the United States.

READ MORE

Teikoku Pharma USA Announces New Drug Application to The U.S. Food and Drug Administration for Docetaxel Injection Concentrate, Non-Alcohol Formula

March 24, 2015

Teikoku Pharma USA (TPU) announced today that it has submitted a 505(b)(2) New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for Docetaxel Injection Concentrate, Non-Alcohol Formula on February 26, 2015 and received an acknowledgment of the receipt from FDA.

READ MORE

Teikoku Pharma USA announced positive results of a recently completed bioavailability (BA) study examining the delivery of TPU-002RA, a 7-day rasagiline patch, for Parkinson’s disease

December 2, 2014

Teikoku Pharma USA announced positive results of a recently completed bioavailability (BA) study examining the delivery of TPU-002RA, a 7-day rasagiline patch, for Parkinson’s disease.

READ MORE

Teikoku Pharma USA, Inc. (TPU) announced that it has settled its claims for false and misleading advertising against JAR Laboratories LLC (JAR) as well as JAR’s counterclaims

September 24, 2013

TPU filed suit in March 2012 in the United States District Court for the Eastern District of Illinois, based in Chicago, alleging claims for false advertising under the Lanham Act and various state laws.

READ MORE

Endo Announces Resolution of Patent Litigation with Watson Pharmaceuticals related to Lidoderm® – Agreement protects Lidoderm® and eliminates uncertainty

May 29, 2012

Endo announced on May 29, 2012 that it reached a settlement with Watson Pharmaceuticals

READ MORE